Design, synthesis, and in vitro and in vivo biological evaluation of dihydroartemisinin derivatives as potent anti-cancer agents with ferroptosis-inducing and apoptosis-activating properties

• Published in: European journal of medicinal chemistry Vol. 281; p. 117018
• Main Authors: Xu, Qian, Deng, Hao, Huang, Xing, Chen, Guo-Qing, Quan, Yin-Sheng, Wang, Ya-Lan, Liu, Jin-Ying, Yan, Rui, Nie, Wen-Zhe, Shen, Qing-Kun, Quan, Zhe-Shan, Guo, Hong-Yan
• Format: Journal Article
• Language: English
• Published: Elsevier Masson SAS 05.01.2025
• Subjects: Anti-tumor; Apoptosis; Dihydroartemisinin; Ferroptosis; Dihydroartemisinin; Ferroptosis; Anti-tumor; Apoptosis
• ISSN: 0223-5234; 1768-3254; 1768-3254
• DOI: 10.1016/j.ejmech.2024.117018

Natural products play a pivotal role in drug development, including their direct use as pharmaceuticals and their structural modification, yielding molecules with enhanced therapeutic potential. The discovery of bioactive molecules, lead compounds, and novel drugs is intrinsically linked to the structural optimization of natural products. In this study, forty-one derivatives of dihydroartemisinin (DHA) were synthesized by incorporating fragments with anti-tumour activity via molecular hybridization, and assessed for their anti-proliferative activity against human cancer cell lines (A549, Bel-7402, HCT-116, and SW620) and normal human liver cells (LO2). Most derivatives exhibited superior anti-proliferative activity compared to DHA. Notably, compound A3, featuring a 4-Cl phenyl carbamate moiety, demonstrated significant anti-proliferative activity against HCT-116 cells with an IC50 of 0.31 μM, making it 16-fold more potent than DHA (IC50 = 5.10 μM). The anti-proliferative mechanism did not involve cytotoxicity (SI = 54.13), indicating its superior safety profile compared to DHA (SI = 1.65). Further mechanistic studies revealed that compound A3 inhibits HCT-116 cell proliferation by modulating the expression of PI3K/AKT/mTOR and STAT3 proteins. STAT3 downregulation represses the expression of the critical ferroptosis protein glutathione peroxidase 4 (GPX4), aggravating the accumulation of reactive oxygen species (ROS) and depletion of glutathione (GSH). This redox imbalance triggers and accelerates ferroptosis. Additionally, A3 also induces apoptosis by damaging mitochondria and influencing MAPK signaling. Compound A3 arrested cells in the G2/M phase by regulating p53 expression. In an HCT-116 xenograft mouse model, compound A3 exhibited significant anti-cancer efficacy, with a tumor growth inhibition rate of 58.7 %. Therefore, compound A3 thus has the potential to serve as a lead compound for the development of new anti-tumor drugs. [Display omitted] •41 DHA derivatives showed enhanced anti-cancer effects, tested on various cell lines.•Compound A3 is 16x more potent than DHA in HCT-116 cells, with an SI of 54.2.•A3 modulates PI3K/AKT/mTOR and STAT3, inducing ROS, ferroptosis, and apoptosis.•In an HCT-116 mouse model, A3 inhibited tumor growth by 58.7 %, showing strong potential.